Zonisamide sodium salt manufacturers
|
| | Zonisamide sodium salt Basic information |
| Product Name: | Zonisamide sodium salt | | Synonyms: | 1,2-BENZISOXAZOLE-3-METHANESULFONAMIDE;BENZO[D]ISOXAZOL-3-YL-METHANESULFONAMIDE;1,2-benzisoxazole-3-methanesulfonamide sodium-potassium salt;1,2-Benzisoxazole-3-methanesulfonamide sodium-potassium salt, Aleviatin sodium-potassium salt, Exceglan sodium-potassium salt, Excegram sodium-potassium salt;1,2-Benzisoxazole-3-methanesulfonamide sodium salt;Zonisamide sodium salt;ZonisaMide (sodiuM);Aleviatin sodium-potassium salt | | CAS: | 68291-98-5 | | MF: | C8H7N2NaO3S | | MW: | 234.21 | | EINECS: | | | Product Categories: | | | Mol File: | 68291-98-5.mol |  |
| | Zonisamide sodium salt Chemical Properties |
| storage temp. | Store at -20°C | | solubility | H2O: >5mg/mL | | form | powder | | color | white to beige | | Water Solubility | H2O: >5mg/mL | | InChI | 1S/C8H7N2O3S.Na/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7;/h1-4H,5H2,(H-,9,11,12);/q-1;+1 | | InChIKey | ZVBIRPKGWOVBLG-UHFFFAOYSA-N | | SMILES | [Na]NS(=O)(=O)Cc1noc2ccccc12 |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | Zonisamide sodium salt Usage And Synthesis |
| Uses | Zonisamide Sodium Salt can be used in biological study of neuroprotective effects of zonisamide target astrocyte. It shows neuroprotection by increasing glutathione, cystine/glutamate exchange transporter expression in mouse CNS catecholaminergic, astrocyte and rat glioma cell and mouse model of 6-OHDA induced hemi-Parkinson''s disease | | Biochem/physiol Actions | Zonisamide sodium salt is an anti-epileptic. It is effective in various animal epilepsy models and humans with both partial and generalized epileptic seizures. Zonisamide sodium salt also scavenges nitric oxide (NO). | | in vivo | Zonisamide sodium (40 mg/kg; i.p.; single daily for 14 days) prevents seizures in FeCl3-induced chronic amygdalar seizures model[2].
Zonisamide sodium (14, 28, 56 mg/kg; i.p.; single daily for 6 weeks) alleviates cardiac hypertrophy and improved cardiac function in rats subjected to AAC (abdominal aortic constriction)[3].
Zonisamide sodium (14, 28, 56 mg/kg; i.p.; single daily for 6 weeks) upregulates Hrd1 expression and accelerates ERAD in the hearts of AAC rats[3]. | Animal Model: | Male Wistar rats (200-250 g; FeCl3-induced chronic amygdalar seizures)[2]. | | Dosage: | 40 mg/kg | | Administration: | Intraperitoneal injection; single daily for 14 days. | | Result: | Showed activity of anti-seizures.
Significantly down-regulated GABA transporters GAT-1 in the hippocampus.
|
| Animal Model: | Adult male Sprague-Dawley rats (100-120 g; cardiac hypertrophy model)[3]. | | Dosage: | 14, 28, 56 mg/kg (dissolved in 1% DMSO) | | Administration: | Intraperitoneal injection; single daily for 6 weeks. | | Result: | Significantly attenuated cardiac hypertrophy and fibrosis.
Increased LV ejection fraction (EF), fractional shortening (FS) and E/A ratio.
Markedly increased the expression of Hrd1 in the hearts of AAC rats.
|
|
| | Zonisamide sodium salt Preparation Products And Raw materials |
|